Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trialPerry B. Shieh, Salvador Rico, Nancy L. Kuntz et al.|The Lancet Neurology|2023Cited by 120
Biallelic loss of function variants in <scp><i>SYT2</i></scp> cause a treatable congenital onset presynaptic myasthenic syndromeSandra Donkervoort, Carsten G. Bönnemann, Erik‐Jan Kamsteeg et al.|American Journal of Medical Genetics Part A|2020Cited by 29